Skip to main content
OpenTrials

Clinical trial condition

Uterine Neoplasms

Explore clinical trials studying Uterine Neoplasms. Study availability and eligibility vary by location and protocol.

2,253 public trials 566 recruiting studies
Refine in advanced search Browse all conditions

Uterine Neoplasms trial results

Recruiting

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074

Conditions
Advanced Endometrial Carcinoma, Endometrial Neoplasms, Female Urogenital Diseases, +11 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States
View all 242 locations
View Trial Details
Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 409 locations
View Trial Details
Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +32 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Newport Beach, California, United States
  • Research Site Jacksonville, Florida, United States
View all 18 locations
View Trial Details
Recruiting

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483

Conditions
Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +10 more
Locations
  • Broward Health Medical Center Fort Lauderdale, Florida, United States
  • Miami Cancer Institute Miami, Florida, United States
  • Mount Sinai Medical Center Miami Beach, Florida, United States
  • Parkview Research Center Fort Wayne, Indiana, United States
View all 75 locations
View Trial Details
Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504

Conditions
Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +11 more
Locations
  • University of South Alabama, Mitchell Cancer Institute ( Site 6033) Mobile, Alabama, United States
  • Alaska Women's Cancer Care ( Site 6036) Anchorage, Alaska, United States
  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014) Irvine, California, United States
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) Orange, California, United States
View all 261 locations
View Trial Details
Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University Cancer and Blood Center LLC Athens, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States
View all 137 locations
View Trial Details
Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703

Conditions
Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Florida Cancer Specialists - South ( Site 7001) Fort Myers, Florida, United States
  • Mount Sinai Comprehensive Cancer Center ( Site 5043) Miami Beach, Florida, United States
  • Mount Sinai Comprehensive Cancer Center ( Site 6000) Miami Beach, Florida, United States
  • Florida Cancer Specialists - East ( Site 7000) West Palm Beach, Florida, United States
View all 155 locations
View Trial Details

Related conditions